These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38385557)

  • 1. Correlating Surface Activity with Interface-Induced Aggregation in a High-Concentration mAb Solution.
    Escobar ELN; Griffin VP; Dhar P
    Mol Pharm; 2024 Mar; 21(3):1490-1500. PubMed ID: 38385557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.
    Kanthe AD; Carnovale MR; Katz JS; Jordan S; Krause ME; Zheng S; Ilott A; Ying W; Bu W; Bera MK; Lin B; Maldarelli C; Tu RS
    Mol Pharm; 2022 Sep; 19(9):3100-3113. PubMed ID: 35882380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.
    Vaclaw C; Merritt K; Griffin VP; Whitaker N; Gokhale M; Volkin DB; Ogunyankin MO; Dhar P
    AAPS PharmSciTech; 2023 Apr; 24(5):104. PubMed ID: 37081185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Polysorbate 80 Grade on the Interfacial Properties and Interfacial Stress Induced Subvisible Particle Formation in Monoclonal Antibodies.
    Vaclaw C; Merritt K; Pringle V; Whitaker N; Gokhale M; Carvalho T; Pan D; Liu Z; Bindra D; Khossravi M; Bolgar M; Volkin DB; Ogunyankin MO; Dhar P
    J Pharm Sci; 2021 Feb; 110(2):746-759. PubMed ID: 32987092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking aggregation and interfacial properties in monoclonal antibody-surfactant formulations.
    Kannan A; Shieh IC; Fuller GG
    J Colloid Interface Sci; 2019 Aug; 550():128-138. PubMed ID: 31055138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic degradation pattern of polysorbate 20 impacts interfacial properties of monoclonal antibody formulations.
    Gregoritza K; Theodorou C; Heitz M; Graf T; Germershaus O; Gregoritza M
    Eur J Pharm Biopharm; 2024 Jan; 194():74-84. PubMed ID: 38042510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Passive Microrheology to Measure the Evolution of the Rheological Properties of NIST mAb Formulations during Adsorption to the Air-Water Interface.
    Escobar ELN; Vaclaw MC; Lozenski JT; Dhar P
    Langmuir; 2024 Mar; 40(9):4789-4800. PubMed ID: 38379175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive Surface Activity of Monoclonal Antibodies and Nonionic Surfactants at the Air-Water Interface Determined by Interfacial Rheology and Neutron Reflectometry.
    Tein YS; Zhang Z; Wagner NJ
    Langmuir; 2020 Jul; 36(27):7814-7823. PubMed ID: 32551695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant Effects on Particle Generation in Antibody Formulations in Pre-filled Syringes.
    Gerhardt A; Mcumber AC; Nguyen BH; Lewus R; Schwartz DK; Carpenter JF; Randolph TW
    J Pharm Sci; 2015 Dec; 104(12):4056-4064. PubMed ID: 26413998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation.
    Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K
    J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension to Predict Surfactant Requirements for Biological Formulations.
    Vargo KB; Stahl P; Hwang B; Hwang E; Giordano D; Randolph P; Celentano C; Hepler R; Amin K
    Mol Pharm; 2021 Jan; 18(1):148-157. PubMed ID: 33253579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-Use Interfacial Stability of Monoclonal Antibody Formulations Diluted in Saline i.v. Bags.
    Kannan A; Shieh IC; Hristov P; Fuller GG
    J Pharm Sci; 2021 Apr; 110(4):1687-1692. PubMed ID: 33141046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gelation of a monoclonal antibody at the silicone oil-water interface and subsequent rupture of the interfacial gel results in aggregation and particle formation.
    Mehta SB; Lewus R; Bee JS; Randolph TW; Carpenter JF
    J Pharm Sci; 2015 Apr; 104(4):1282-90. PubMed ID: 25639229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the Combined Impact of Temperature and Application of Interfacial Dilatational Stresses on Surface-mediated Protein Particle Formation in Monoclonal Antibody Formulations.
    Griffin VP; Merritt K; Vaclaw C; Whitaker N; Volkin DB; Ogunyankin MO; Pace S; Dhar P
    J Pharm Sci; 2022 Mar; 111(3):680-689. PubMed ID: 34742729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.